epirubicin has been researched along with Ventricular Dysfunction, Left in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (42.31) | 29.6817 |
| 2010's | 14 (53.85) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Adam, G; Azar, M; Beitzen-Heineke, A; Goy, Y; Lund, GK; Molwitz, I; Muellerleile, K; Müller, V; Petersen, C; Schön, G; Seiffert, K; Shihada, S; Stehning, C; Tahir, E | 1 |
| Geisler, J; Gravdehaug, B; Gulati, G; Hagve, TA; Heck, SL; Hoffmann, P; Norseth, J; Omland, T; Ree, AH; Røsjø, H; Steine, K | 1 |
| Chen, F; Chen, H; He, B; Kang, Y; Shen, L; Shen, X; Wang, W; Xiao, F; Zhao, H | 1 |
| Jiang, Y; Peng, Q; Tang, Z; Zhou, Q | 1 |
| Enescu, OA; Florescu, M; Jinga, D; Magda, LS; Vinereanu, D | 1 |
| Aftimos, P; Ameye, L; Beauduin, M; Bejarano Hernández, S; Cornez, N; de Azambuja, E; Delhaye, F; Diaz, M; Focan, C; Lemort, M; Paesmans, M; Piccart-Gebhart, M; Shih-Li, C; Suter, T; Vandenbossche, S; Vindevoghel, A | 1 |
| Han, Q; Hu, R; Irwin, DM; Li, H; Man, Z; Mao, Y; Niu, G; Tan, H; Wang, X; Zhang, J; Zhang, Q; Zhang, X | 1 |
| Cadeddu, C; Colonna, P; Dessì, M; Hagendorff, A; Madeddu, C; Mantovani, G; Mercuro, G; Piras, A; Scartozzi, M | 1 |
| Bi, X; Deng, Y; Li, C; Wu, Y; Zeng, F; Zhao, C; Zhu, Y | 1 |
| Albrile, F; Biggi, A; Bobbio, M; Feola, M; Francini, A; Garrone, O; Merlano, M; Occelli, M; Visconti, G | 1 |
| Caron, HN; Hauptmann, M; Kok, WE; Koning, CC; Kremer, LC; Oldenburger, F; van Dalen, EC; van den Bos, C; van der Pal, HJ; van Leeuwen, FE | 1 |
| Cadeddu, C; Deidda, M; Dessì, M; Madeddu, C; Mantovani, G; Massa, E; Mercuro, G; Piras, A | 1 |
| Appel, JM; Mortensen, CE; Nielsen, DL; Skagen, K; Sogaard, P | 1 |
| Adoh, A; Adoubi, I; Adoubi, K; Anzouan-Kacou, JB; Didi-Kouko, C; Pio, M; Tegnan, A | 1 |
| AitRaiss, M; Benhmidoun, MA; Derhem, N; Elalouani, C; Elguenzri, A; Elhattaoui, M; Elomrani, A; Errehmouni, A; Faouzi, R; Khouchani, M; Mahmal, L; Rida, H; Tahri, A; Tazi, I | 1 |
| Deng, LC; Gao, CH; Shen, D; Shen, WS; Zhang, H | 1 |
| Carrió, I; Dalesio, O; Estorch, M; Hoefnagel, CA; López-Pousa, J; ten Bokkel Huinink, WW; Valdés Olmos, RA | 1 |
| Aldrighetti, D; Baldini, E; Bolognesi, A; Bruzzi, P; Carnino, F; Conte, PF; Gallo, L; Giannessi, P; Orlandini, C; Prochilo, T; Rosso, R; Salvadori, B; Venturini, M | 1 |
| Barats, JC; Bonneterre, J; Chapelle-Marcillac, I; Clavère, P; Datchary, J; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Monnier, A; Montcuquet, P; Roché, H; Van Praagh, I; Veyret, C | 1 |
| Azarnia, N; Chan, S; Davidson, N; Erdkamp, F; Juozaityte, E; Lee, LW; Pluzanska, A | 1 |
| Bonneterre, J; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Luporsi, E; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P | 1 |
| Cadeddu, C; Deidda, M; Dessì, M; Madeddu, C; Mantovani, G; Massa, E; Mercuro, G; Piras, A; Serpe, R | 1 |
| Duncea, C; Pripon, S; Radulescu, D; Radulescu, LI | 1 |
| Bengala, C; Carnino, F; Conte, P; Del Mastro, L; Gallo, L; Lionetto, R; Michelotti, A; Montanaro, E; Rosso, R; Tibaldi, C; Venturini, M | 1 |
| Boyer, M; Gurney, H; Lewis, C; McKendrick, J; Millward, M; Richardson, G; Rischin, D; Smith, J; Toner, G | 1 |
| Baccheta, G; Belotti, G; Ciotti, R; Cremonesi, M; Facchi, E; Gatti, C; Ucci, G | 1 |
14 trial(s) available for epirubicin and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antibiotics, Antineoplastic; Benzimidazoles; Biomarkers; Biphenyl Compounds; Breast Neoplasms; Cardiotoxicity; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Epirubicin; Female; Humans; Metoprolol; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Protein Precursors; Tetrazoles; Treatment Outcome; Troponin I; Troponin T; Ventricular Dysfunction, Left | 2017 |
Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Early Diagnosis; Echocardiography; Elasticity Imaging Techniques; Epirubicin; Female; Humans; Middle Aged; Reproducibility of Results; Sensitivity and Specificity; Ventricular Dysfunction, Left | 2014 |
Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Echocardiography; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Heart Failure; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Survival Rate; Ventricular Dysfunction, Left | 2015 |
Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Breast Neoplasms, Male; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Stroke Volume; Troponin I; Ventricular Dysfunction, Left | 2011 |
Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antibiotics, Antineoplastic; Benzimidazoles; Benzoates; Cytokines; Echocardiography, Doppler; Epirubicin; Female; Heart; Humans; Inflammation; Inflammation Mediators; Male; Middle Aged; Myocardial Contraction; Oxidative Stress; Renin-Angiotensin System; Systole; Telmisartan; Ventricular Dysfunction, Left | 2010 |
Tissue-Doppler assessment of cardiac left ventricular function during short-term adjuvant epirubicin therapy for breast cancer.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Middle Aged; Treatment Outcome; Ultrasonography; Ventricular Dysfunction, Left | 2011 |
Protective effects of salidroside on epirubicin-induced early left ventricular regional systolic dysfunction in patients with breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antioxidants; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography; Epirubicin; Female; Glucosides; Humans; Middle Aged; Phenols; Reactive Oxygen Species; Rhodiola; Ventricular Dysfunction, Left | 2012 |
High sensitivity of radiolabelled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Doxorubicin; Epirubicin; Follow-Up Studies; Heart; Humans; Indium Radioisotopes; Middle Aged; Myocardium; Myocytes, Cardiac; Myosins; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Stroke Volume; Ventricular Dysfunction, Left | 2002 |
Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Epirubicin; Female; Heart Failure; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Risk Factors; Ventricular Dysfunction, Left | 2004 |
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Heart; Heart Failure; Humans; Lymphatic Metastasis; Middle Aged; Prospective Studies; Stroke Volume; Ventricular Dysfunction, Left | 2004 |
Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Liposomes; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left | 2004 |
Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Biomarkers; Creatine Kinase; Echocardiography, Doppler; Epirubicin; Female; Glutathione Peroxidase; Heart Failure; Humans; Inflammation Mediators; Interleukin-6; Male; Middle Aged; Myocardial Contraction; Myoglobin; Natriuretic Peptide, Brain; Oxidative Stress; Reactive Oxygen Species; Receptors, Interleukin-6; Stroke Volume; Troponin I; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Septum | 2007 |
Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Cardiovascular Agents; Epirubicin; Female; Heart Failure; Humans; Injections, Intravenous; Middle Aged; Razoxane; Treatment Outcome; Ventricular Dysfunction, Left | 2000 |
A phase II trial of paclitaxel and epirubicin in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Ventricular Dysfunction, Left | 2000 |
12 other study(ies) available for epirubicin and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT.
Topics: Breast Neoplasms; Cardiotoxicity; Epirubicin; Female; Heart Diseases; Humans; Magnetic Resonance Imaging; Magnetic Resonance Imaging, Cine; Predictive Value of Tests; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Subclinical Anthracycline-Induced Cardiotoxicity in the Long - Term Follow-Up of Lymphoma Survivors: A Multi-Layer Speckle Tracking Analysis.
Topics: Adult; Aged; Analysis of Variance; Anthracyclines; Antibiotics, Antineoplastic; Cardiotoxicity; Case-Control Studies; Cross-Sectional Studies; Echocardiography; Epirubicin; Female; Follow-Up Studies; Heart; Humans; Lymphoma, B-Cell; Male; Middle Aged; Myocardium; Observer Variation; Reference Values; Risk Factors; Statistics, Nonparametric; Stroke Volume; Ventricular Dysfunction, Left; Young Adult | 2018 |
[Velocity vector imaging assessment of early epirubicin-induced myocardial damage].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Flow Velocity; Breast Neoplasms; Carcinoma, Ductal, Breast; Cardiac Volume; Case-Control Studies; Echocardiography; Elasticity Imaging Techniques; Epirubicin; Female; Humans; Middle Aged; Ventricular Dysfunction, Left | 2013 |
Xinmailong mitigated epirubicin-induced cardiotoxicity via inhibiting autophagy.
Topics: Animals; Autophagy; Cardiotonic Agents; Cardiotoxicity; Collagen; Disease Models, Animal; Drugs, Chinese Herbal; Epirubicin; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Gene Expression Regulation; Heart Diseases; Hypertrophy, Left Ventricular; Male; Matrix Metalloproteinase 9; Myocardium; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Stroke Volume; Time Factors; Tissue Inhibitor of Metalloproteinase-4; Tissue Inhibitor of Metalloproteinases; Transforming Growth Factor beta1; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2016 |
Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Drug Administration Schedule; Drug Synergism; Early Diagnosis; Echocardiography, Doppler, Pulsed; Epirubicin; Female; Humans; Middle Aged; Myocardial Contraction; Predictive Value of Tests; Prospective Studies; Risk Factors; Time Factors; Trastuzumab; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |
Evaluation of epirubicin-induced cardiotoxicity by two-dimensional strain echocardiography in breast cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Echocardiography, Doppler; Epirubicin; Female; Humans; Middle Aged; Ventricular Dysfunction, Left; Ventricular Function, Left | 2009 |
Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cohort Studies; Doxorubicin; Echocardiography; Epirubicin; Female; Follow-Up Studies; Humans; Infant; Linear Models; Logistic Models; Male; Multivariate Analysis; Neoplasms; Netherlands; Prevalence; Prospective Studies; Risk Factors; Ventricular Dysfunction, Left | 2010 |
[Early detection of anthracyclines cardiotoxicity by tissue Doppler echocardiography about 45 cases at Abidjan institute of cardiology].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Cardiomyopathies; Cardiotoxins; Developing Countries; Dose-Response Relationship, Drug; Doxorubicin; Echocardiography, Doppler; Epirubicin; Female; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Mitral Valve; Neoplasms; Stroke Volume; Systole; Togo; Ventricular Dysfunction, Left | 2013 |
[Short and medium term cardiotoxicity of anthracyclins: a prospective study].
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Morocco; Myocardial Contraction; Myocarditis; Neoplasms; Prospective Studies; Risk Factors; Time Factors; Ultrasonography; Ventricular Dysfunction, Left | 2012 |
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Heart; Humans; Incidence; Middle Aged; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left | 2006 |
Left ventricular diastolic performance in breast cancer survivors treated with anthracyclines.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Diastole; Echocardiography; Epirubicin; Female; Humans; Middle Aged; Ventricular Dysfunction, Left; Ventricular Function, Left | 2008 |
Prospective evaluation of anthracycline-related early cardiac damage: how do we monitor it?
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Epirubicin; Female; Heart; Humans; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Radionuclide Ventriculography; Ultrasonography; Ventricular Dysfunction, Left | 2001 |